Journal
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY
Volume 4, Issue 4, Pages 231-242Publisher
WILEY
DOI: 10.1002/psp4.28
Keywords
-
Categories
Funding
- Advanced Quantitative Sciences Department of Novartis
Ask authors/readers for more resources
Chronic infection with hepatitis C virus (HCV) affects about 170 million people worldwide and is a major cause of liver complications. Mathematical modeling of viral kinetics under treatment has provided insight into the viral life cycle, treatment effectiveness, and drugs' mechanisms of action. Here we review the implications of viral kinetic models at the different stages of development of anti-HCV agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
